Menopausal hormone therapy in healthy women: a new look at an old topic?

Therapeutic personalisation II: pharmacogenetics

Therapeutic personalisation I: Practical aspects of pharmacokinetic monitoring

Beyond statins: evidence for other lipid-lowering drugs in patients with atherosclerotic cardiovascular disease

Surrogate outcomes and fast-track drug approval

Glucagon-like peptide 1 receptor agonists (GLP1a) and the problem of obesity

Use of fluid therapy in clinical practice

Safe drug use in patients with cirrhosis

Long-acting injectable antipsychotics in schizophrenia

Interchage of biosimilar medicines: effective, safe and efficient

Topical corticosteroids during childhood

Infection risk of targeted synthetic drugs used in immune-mediated inflammatory diseases

An update on pre-hospital management of major trauma

What role can dabigatran, rivaroxaban and apixaban play in the future?

Biotechnology drugs and cancer. All that glitters is not gold

Ibandronate and the prevention of non-vertebral fractures. A critical appraisal of two meta-analyses on individual patient data

DTB Navarre. Vol 18, No 2. March - April 2010

Patient safety, beware of medication errors!

Suicide and antidepressants

Rosuvastatin and the JUPITER trial. A critical appraisal